Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study
Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 6207-6216
DOI: 10.1111/dom.70778 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.05.2026. Verfasst von Rakesh Sahay und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Osmania General Hospital, Hyderabad, Telangana, India. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Metformin, Sitagliptin Phosphate. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sun Pharma Laboratories Limited.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
This study assessed the efficacy and safety of a triple fixed‐dose combination (FDC) of sitagliptin, metformin, and glimepiride versus co‐administered metformin and glimepiride in Indian patients with uncontrolled Type 2 diabetes (T2D). Materials and Methods In this Phase 3, randomised, double‐blind, double‐dummy study, adult patients with T2D and glycated haemoglobin (HbA 1c ) of 8%–11%, despite treatment with metformin and glimepiride, were randomised 1:1 to triple FDC of sitagliptin 50 mg, metformin 1000 mg and glimepiride 1 mg (SITA + MET + GLIM group) or metformin 1000 mg and glimepiride 2 mg (Co‐administration group) for 16 weeks. Patients assigned to the SITA + MET + GLIM group could continue treatment for a 12‐week open‐label period. The primary endpoint was the change in HbA 1c from baseline to Week 16.
Results
Overall, 190 patients were randomised to the SITA + MET + GLIM group and 202 to the Co‐administration group. The least squares mean (standard error) change from baseline in HbA 1c at Week 16 was −1.79 (0.07%) in the SITA + MET + GLIM group and −1.27 (0.06%) in the co‐administration group (estimated treatment difference −0.51; 95% confidence interval [CI] −0.69 to −0.33; p < 0.0001). The proportion of patients with HbA 1c below 7% at Week 16 was 32.1% in the SITA + MET + GLIM group and 12.6% in the Co‐administration group ( p < 0.0001). Adverse events occurred in 25 patients (13.2%) in the SITA + MET + GLIM group and 30 patients (14.9%) in the Co‐administration group.
Conclusions
The triple FDC was superior to co‐administered metformin and high‐dose glimepiride for achieving glycaemic control and was well tolerated in Indian patients with T2D. Trial Registration Clinical Trials Registry–India identifier: CTRI/2021/11/038169 (registered on 22 November 2021); URL: https://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjI1Mjk=&Enc=&userName=
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Osmania General Hospital, Hyderabad, Telangana, India.
- Citizen Hospital, Bengaluru, Karnataka, India.
- Department of Medicine, Maya Hospital and Maternity Centre, Kanpur, Uttar Pradesh, India.
- Department of Medicine, Government Medical College and Government General Hospital, Srikakulam, Andhra Pradesh, India.
- Department of Diabetology, Kovai Diabetes Speciality Centre and Hospital, Coimbatore, Tamil Nadu, India.
- Department of Medicine, Priyadarshani Nursing Home, Virar, Maharashtra, India.
ORCID-Profile: Dipak Patil
Förderung
- Sun Pharma Laboratories Limited
Zitieren
APA
Sahay, R., Gowda, A., Singh, M. K., Rao, A. G., Duraisamy, R., Gangwani, D., Shukla, J., Agarwal, V., Patil, S. S., C, A., K N, S. B., Palawat, A., Gofne, S. K., Sahoo, A. K., Rai, P. K., Shaikh, R., Saha, S., Patil, D., Ghadge, P., …, & Joglekar, S. (2026). Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study. Diabetes, Obesity and Metabolism, 28(7), 6207-6216. https://doi.org/10.1111/dom.70778
Vancouver
Sahay R, Gowda A, Singh MK, Rao AG, Duraisamy R, Gangwani D, et al. Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study. Diabetes, Obesity and Metabolism. 2026;28(7):6207-6216. doi:10.1111/dom.70778
BibTeX
@article{Sahay2026,
author = {Sahay, Rakesh and Gowda, Ambanna and Singh, Manish Kumar and Rao, A Gopal and Duraisamy, Ramesh and Gangwani, Dinesh and Shukla, Jitendra and Agarwal, Vikas and Patil, Sandesh Sahebarao and C, Ambrish and K N, Satish Babu and Palawat, Arvind and Gofne, Sandip Krishnrao and Sahoo, Abhay Kumar and Rai, Pradeep Kumar and Shaikh, Raisa and Saha, Shruti and Patil, Dipak and Ghadge, Pravin and Patel, Piyush and Lakhwani, Lalit and Mehta, Suyog and Joglekar, Sadhna},
title = {Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {7},
pages = {6207--6216},
doi = {10.1111/dom.70778}
}
EUVIMED